spacer
home > ebr > Winter 2002
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2002
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of this issue  
view
Opinion - As 2002 closes and a new year begins, Dr Helen Abbott introduces our brand new readers' forum page  
view
bullet
STRATEGY AND FINANCE
Despite significant revaluation and restructuring, the biotech sector has reversed its downward trend. In a review of the industry's performance in 2002, G Steven Burrill, CEO of Burrill & Company, reassures us that Biotech Endures  
view
The FT Global Biotech Conference in London recently brought together strategic thinkers from each side of the pond. Dr Helen Abbott, Senior Consultant at Technomark Consulting Services and Editor of EBR, was there  
view
Dr Helen Abbott, EBR's Editor, reports on the 10th Annual BioPartnering Europe (BPE) conference, which covered many diverse aspects of partnering  
view
Science and Innovation
Dr Will West, Product Development Director at CellFactors, explains how cell implants and engineered tissues will be able to cure a broad range of health conditions, in Realising the Potential of Human Cells for Therapy  
view
In Stem Cells Find a UK Niche - The UK National Stem Cell Initiative, Dr John Sinden, Chief Scientific Officer of ReNeuron Holdings plc, introduces an important new resource for UK researchers 

 
view
Traditional validation of potential drug targets can be extremely time-consuming. In Target Validation in the Nervous System using Herpes Simplex Viral Vectors, Dr James Palmer, Senior Scientist, and Dr Robert Coffin, Chief Scientific Officer at BioVex Ltd, propose an alternative method  
view
Bacterial resistance to antibiotics has become a serious threat to public health. Anne Gill, Head of Microbiology at PanTherix Ltd, reminds us of the need for Novel Antibiotics to Counteract the Global Threat of Superbugs  
view
Before attempting drug design we must understand the mechanisms that cause disease at a genetic level. Dr Bob Jackson, Executive Director of R&D at Cyclacel, takes us From Genes to Drugs  
view
Understanding the biological mechanisms that regulate brain function is a daunting task. In Investigating Biomolecular Interactions in Neuropathology: The Role of SPR, Stefan Löfås, Vice President and Chief Scientific Officer of Biacore AB, reviews a powerful new tool  
view
Dr Günter Kraus, Vice President of Research and Development at amaxa GmbH, explores recent progress in the development of Non-Viral Gene Delivery Methods  
view
The large volume of data generated by high-throughput systems means that the selection of relevant information is crucial. Dr Nora Benhabilès, Director of Bioinformatics, and Professor Gérard Marguerie, Chief Scientific Officer at CliniGenetics, discuss New Challenges in Physiogenomics  
view
bullet
Legal, Regulatory and Public Policy
Nick McCooke, Chief Executive Officer of Solexa, considers the potential of genome sequencing services for individuals, in Personal Genomes  
view
In Principled Pragmatism: The UK Perspective on Embryonic Stem Cell Research, Claire Foster of The Church of England's Public Affairs Unit, unravels a complex ethical debate  
view
bullet
PATENTING POLICY AND PRACTICE
In the post-genomic world, the milestones as well as the endpoints of drug discovery must be protected. Arie M Michelsohn, PhD, JD, Member of the Bio/Pharmaceutical Practice Group at Finnegan, Henderson, Farabow, Garrett & Dunner LLP, goes Beyond the Patented Genome: Protecting Discovery in the New Biology Estate Space  
view
Professor Matthias Herdegen, Director of the Institute of International Law and the Institute for Public Law, University of Bonn, explains Patent Protection for Genes and Other Parts of the Human Body under EC Law  
view
Thierry Calame, Attorney at Law with Lenz & Staehelin, proposes methods of Dealing with the Pitfalls of Intellectual Property Co-Ownership in International Biopharmaceutical R&D Joint Ventures  
view
In Part One of a two-part series, Dr Uta Kцster, Associate with Bardehle Pagenberg, considers Absolute or Limited Product Protection for Biotech Inventions under the relevant EC Directive  
view
bullet
Regional Focus: Scandinavia
Sirkka Aura, CEO of Invest in Finland, explains why the country provides a favourable social and economic climate for biotech to prosper, in Overview of the Biotechnology Industry in Finland  
view
In Crossbreeding and Commercial Consolidation in the Uppsala Biotech Cluster, Per Odebrant, Freelance Science and Business Journalist, introduces us to the 'Uppsala Phenomenon'  
view
Dr Helen Abbott, Senior Consultant at Technomark Consulting Services and EBR's Editor, reports on the first Scandinavian BiotechArena Event, held in Malmц, Sweden  
view
bullet
CORDIA REVIEW
A taste of what to expect at Cordia EuropaBio Convention 2003  
bullet
APPLIED RESEARCH, DEVELOPMENT AND PRODUCTION
Dr Alcide Barberis, Chief Scientific Officer of ESBATech AG, describes the applicability of cell-based assays to the early phase of drug discovery, in Cell-Based High-Throughput Screens for Drug Discovery  
view
In The Splice of Life, Fabien Schweighoffer PhD, Executive Vice-President of Therapeutic Programs at ExonHit Therapeutics, investigates the advantages of examining cellular events at the mRNA level  
view
How to Truncate RNA Preparation in cRNA Labelling Reactions Without Sacrificing Microarray Performance? Dr Jenny Xiao, Application Scientist at Agilent Technologies, explains  
view
John C Anders, K Chad Bastian and Glenn E Petrie, Research Associates at AAI International, explore the Determination of Absorptivity Constants for Biopharmaceutical Protein Products by Amino Acid Analysis  
view
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Synpromics announces a research collaboration with GE Healthcare to extend the toolbox for production of biologics

Edinburgh, UK, 4th January 2017 – Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

Industry Events

Pharma Packaging and Labeling East Coast 2018

21-22 February 2018, Philadelphia, USA

The 10th Annual Pharma Packaging and Labeling East Coast event aims to create an environment where commercial packaging and labeling teams work together to successfully manage both creative and regulatory demands while safeguarding products and protecting patients.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement